Trial Profile

A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-centre, Global Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum-based, Concurrent Chemoradiation Therapy (eVOLVE-Cervical)

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 06 May 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Volrustomig (Primary) ; Infliximab; Mycophenolate mofetil
Indications Adenocarcinoma; Adenosquamous carcinoma; Cervical cancer; Squamous cell cancer
Focus Registrational; Therapeutic Use
Acronyms eVOLVE-Cervical; eVOLVECervical
Sponsors AstraZeneca; AstraZeneca AB

27 Jan 2026 Planned End Date changed from 18 Oct 2029 to 30 Sep 2030.
27 Jan 2026 Planned primary completion date changed from 17 Nov 2026 to 26 Nov 2027.
18 Aug 2025 Planned number of patients changed from 832 to 831.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com